Adverum Biotechnologies Inc expected to post a loss of $1.36 a share - Earnings Preview

Adverum Biotechnologies

14/03/2025 11:25

Adverum Biotechnologies Inc ADVM.OQ ADVM.O is expected to show no change in quarterly revenue when it reports  results on March 17 (estimated) for the period ending December 31 2024

​LSEG's mean analyst estimate for Adverum Biotechnologies Inc is for a loss of $1.36 per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Adverum Biotechnologies Inc is $32.00​, above​ its last closing price of $4.50. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATEÂŪ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-1.29
-1.31
-1.30
Beat
0.5
Jun. 30 2024
-1.44
-1.47
-0.89
Beat
39.4
Mar. 31 2024
-1.55
-1.40
-1.50
Missed
-6.8​
Dec. 31 2023
-3.35
-3.37
-2.30
Beat
31.7
​​Sep. 30 2023
-3.06
-3.15
-3.30
Missed
-4.7
Jun. 30 2023
-3.12
-3.29
-3.10
Beat
5.7​
Mar. 31 2023
-3.20
-3.20
-2.90
Beat
9.5
Dec. 31 2022
-3.72
-3.62
-3.30
Beat
8.9

This summary was machine generated March 14 at 11:25 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)